Therapy Combo Improves Radiographic PFS in Prostate Cancer

Published Date: 02 Jun 2026

A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.

Read Full News

Latest News

Belzutifan Plus Pembro Approved for Adjuvant RCC

LITESPARK-022 trial reports a 28% decrease in risk for disease recurrence or death.

Simpler Screening Criteria Could Catch More Lung Cancers

A study of nearly 1 million veterans suggests that simpler lung cancer screening eligibility — based on smoking duration — would sharply reduce missed cancers and narrow disparities.

Breast Cancer Genetic Testing Need in Black Women Identified

A large population study of young Black women aged 50 years or younger with invasive breast cancer highlights the importance of genetic testing in this population.

NHS Offers Targeted Radiotherapy for Early Prostate Cancer

Eligible men with early prostate cancer can now be offered a high-precision radiotherapy technique on the NHS in England.

Smartphone App Detects Eye Cancers From Photos

A smartphone app that analyzes images of the eye may enable early screening for cancers of the eye surface, flag lesions at high risk for specialist review, and expand access beyond clinics.

Novel ADC Improves Survival in Metastatic TNBC

Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.

Todays Updates

HIV Care Coordination Program May Reduce Deaths in NYC

New York City’s revised Care Coordination Program may help reduce risks for all-cause and HIV-related deaths among people with HIV infection, including those at the highest risk for poor outcomes.

Teplizumab Approved for Pediatric Stage 3 Type 1 Diabetes

The drug was previously approved for stage 2 T1D.

One in Four Teen Girls and Young Women at Risk for PMOS

Findings suggest young females should be assessed and, if at risk, monitored.

Palopegteriparatide Benefits Sustained Beyond 3 Years

Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.

Testosterone Prescribing Often Ignores Guidelines

Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.

Encaleret Shows Rapid Response in ADH1

The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels.

Off-Label Rxs: Thinking Out of the Box for Skin Diseases

Off-label alternatives for FDA-approved therapies can be as effective, cheaper, and in some cases safer despite never having been submitted for regulatory approval.

Todays Updates

HIV Care Coordination Program May Reduce Deaths in NYC

New York City’s revised Care Coordination Program may help reduce risks for all-cause and HIV-related deaths among people with HIV infection, including those at the highest risk for poor outcomes.

Teplizumab Approved for Pediatric Stage 3 Type 1 Diabetes

The drug was previously approved for stage 2 T1D.

One in Four Teen Girls and Young Women at Risk for PMOS

Findings suggest young females should be assessed and, if at risk, monitored.

Palopegteriparatide Benefits Sustained Beyond 3 Years

Final results from the PaTHway trial show the long-acting parathyroid hormone therapy enabled patients with hypoparathyroidism to achieve independence from high-dose calcium and vitamin D supplements.

Testosterone Prescribing Often Ignores Guidelines

Only 12% of patients prescribed testosterone underwent appropriate diagnostic testing, and overprescribing was common in a single-center US study.

Encaleret Shows Rapid Response in ADH1

The oral modulator of the calcium-sensing receptor targets the causes of ADH1, significantly improving serum and urine calcium levels.

Off-Label Rxs: Thinking Out of the Box for Skin Diseases

Off-label alternatives for FDA-approved therapies can be as effective, cheaper, and in some cases safer despite never having been submitted for regulatory approval.

Latest News

LITESPARK-022 trial reports a 28% decrease in risk for disease recurrence or death.

A study of nearly 1 million veterans suggests that simpler lung cancer screening eligibility — based on smoking duration — would sharply reduce missed cancers and narrow disparities.

A large population study of young Black women aged 50 years or younger with invasive breast cancer highlights the importance of genetic testing in this population.

Eligible men with early prostate cancer can now be offered a high-precision radiotherapy technique on the NHS in England.

A smartphone app that analyzes images of the eye may enable early screening for cancers of the eye surface, flag lesions at high risk for specialist review, and expand access beyond clinics.

Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.

News All Time

FDA Approves Novel Targeted Therapy for Rare Blood Cancer

The CD123-directed antibody and alkylating agent conjugate led to complete remission or clinical complete remission in nearly 70% of treatment-naive patients in a single arm study.

Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer

The combination therapy is approved for BCG-naive patients with high-risk non-muscle-invasive disease.

Can Fasting Around Chemo Improve Ovarian Cancer Outcomes?

Women with ovarian cancer who fast shortly before and after chemotherapy have lower insulin levels, stronger tumor responses, and longer progression-free survival in a small randomized trial.

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

NP-Led Outreach Ups Cancer Screening in Rural Women Veterans

A nurse practitioner-led outreach program improves the rates of breast and cervical cancer screening among women veterans in rural areas, a retrospective study shows.

Less Mental Decline With Darolutamide vs Enzalutamide in PC

Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

Revolutionary Cancer Tx Could Transform Autoimmune Disease

Researchers are testing CAR T-cell therapy as a way to reset the immune system in lupus, Graves’ disease and other conditions where the body’s defenses go rogue.

France Expands 2026 Vaccination Rules Amid Resurgence

Nearly 300 experts warn that rising vaccine misinformation is reversing gains — measles and meningococcal infections are resurging while France updates the 2026 schedule.

Antibiotic Stewardship: Five Tips to Reduce Resistance

Clinicians continue prescribing antibiotics unnecessarily despite growing evidence supporting shorter, targeted, and reassessed treatment strategies.

FDA Expands Use of T-DXd in Early HER2+ Breast Cancer

The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?

Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.

Too Many Chest CTs for Incidental Lung Nodules?

Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.

FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer

The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.

All-Oral Treatment Combo for AML Earns FDA Nod

The combo, decitabine and cedazuridine tablets plus venetoclax, was approved for adults aged 75 and older and adults with comorbidities that preclude intensive induction chemotherapy.

Only 1 in 4 Eligible Adults Receive Lung Screening

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

Recommended News For You

Can Oligonucleotide Infusions Really Fix Lyme, Cancer, and Other Diseases?

Low-Dose Radiation Provides Almost Perfect Control Over Slow-Growing Lymphoma.

Getting More Done With Less Blood.

A study on lung cancer provides additional proof of the value of screening.

Trump slashed US cancer research by 31 percent: Senate report

No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer

O. A. J. Simpson passes away from cancer.

Recommended Articles For You

Living with Shwachman-Diamond Syndrome: A Journey of Hope and Strength 

Decoding the Padua Score to Prevent Blood Clots in High-Risk Patients 

From Bruises to Blood Clots: Everything You Need to Know about Hematoma  

Impact of Hormone Therapy Cessation on Tumor Growth: Case Study of Ki-67 Reduction 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen

2.

'Ticking Time Bomb'; Jimmy Carter's Lasting Impact on Cancer; Breast Cancer-CVD Link

3.

Millions of men could benefit from faster scan to diagnose prostate cancer

4.

Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma

5.

Key mechanism behind prostate cancer drug resistance reveals potential new treatment strategy

1.

Modern Approaches to Detecting Residual Disease: Clinical Utility and Future Trends

2.

A Closer Look at the Effects of Sickle Cell on Eyesight

3.

Uncovering the Role of Pap Smear in Oncology: A New Frontier in Cancer Detection

4.

Chronic Cancer Survivorship: Managing Long-Term Outcomes with Precision Care

5.

Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

2.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V

3.

Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World

4.

First Line Combination Therapy- The Overall Survival Data in NSCLC Patients

5.

Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot